Case number 2017-2173
Novartis Pharmaceuticals Corp v. Breckenridge Pharmaceutical > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | NOVARTIS PHARMACEUTICALS CORP v. BRECKENRIDGE PHARMACEUTICAL [OPINION - PRECEDENTIAL] [precedential] (0) |
| Feb 15, 2019 | 85 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [586208] [17-2173, 17-2175, 17-2176, 17-2178, 17-2179, 17-2180, 17-2182, 17-2183, 17-2184] [PBC] [Entered: 02/15/2019 08:48 AM] (2) |
| Feb 8, 2019 | 84 | ORDER filed denying [80] petition for en banc rehearing filed by West-Ward Pharmaceuticals International Limited. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [584456] [PBC] [Entered: 02/08/2019 12:27 PM] (2) |
| Jan 9, 2019 | 83 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: certificate of interest Docket No. [82], ERROR: Name of party represented (item no. 1) does not match official caption. CORRECTION: In the future, counsel must either use party name as seen in official caption or move to have the caption revised. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [576862] [JAB] [Entered: 01/09/2019 10:58 AM] (0) |
| Jan 8, 2019 | 82 | Amended Certificate of Interest for the Appellee West-Ward Pharmaceuticals International Limited. Service: 01/08/2019 by email. [576740] [17-2173] [William Jay] [Entered: 01/08/2019 05:47 PM] (5) |
| Jan 8, 2019 | 81 | 18 paper copies of the petition for en banc rehearing [80] received from Appellee West-Ward Pharmaceuticals International Limited. [576727] [JAB] [Entered: 01/08/2019 04:28 PM] (0) |
| Jan 8, 2019 | 80 | Petition for en banc rehearing filed by Appellee West-Ward Pharmaceuticals International Limited. Service: 01/08/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 01/10/2019 [576590] [17-2173] [William Jay] [Entered: 01/08/2019 10:47 AM] (42) |
| Jan 8, 2019 | 79 | NOTICE OF NON-COMPLIANCE: The submission of Appellee West-Ward Pharmaceuticals International Limited, Petition for rehearing en banc [78], is not in compliance with the rules of this court (see attached). Service as of this date by the Clerk of Court.[576545] [JAB] [Entered: 01/08/2019 08:39 AM] (1) |
| Jan 7, 2019 | 78 | Petition for en banc rehearing filed by Appellee West-Ward Pharmaceuticals International Limited. Service: 01/07/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 01/09/2019 [576517] [17-2173] This document is non-compliant. See Doc. No. [79]. [William Jay] [Entered: 01/07/2019 11:58 PM] (42) |
| Dec 7, 2018 | 77 | JUDGMENT filed. REVERSED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [570131] [17-2173, 17-2175, 17-2176, 17-2178, 17-2179, 17-2180, 17-2182, 17-2183, 17-2184] [PBC] [Entered: 12/07/2018 10:16 AM] (2) |
| Dec 7, 2018 | 76 | OPINION filed for the court by Prost, Chief Judge; Wallach, Circuit Judge and Chen, Circuit Judge. Precedential Opinion. [570129] [17-2173, 17-2175, 17-2176, 17-2178, 17-2179, 17-2180, 17-2182, 17-2183, 17-2184] [PBC] [Entered: 12/07/2018 10:15 AM] (20) |
| Nov 9, 2018 | 75 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [72], attorney entry of appearance Docket No. [70], ERROR: attorneys have updated the address associated with their ECF accounts, but have not updated emails (which are still associated with Fitzpatrick Cella). CORRECTION: counsel should update all info associated with ECF accounts promptly. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [563818] [SJ] [Entered: 11/09/2018 09:34 AM] (0) |
| Nov 7, 2018 | 74 | Amended Certificate of Interest for the Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 11/07/2018 by email. [563417] [17-2173] [Laura Fishwick] [Entered: 11/07/2018 04:56 PM] (4) |
| Nov 7, 2018 | 73 | Amended Entry of appearance for Laura K. Fishwick as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 11/07/2018 by email. [563416] [17-2173] [Laura Fishwick] [Entered: 11/07/2018 04:54 PM] (4) |
| Nov 7, 2018 | 72 | Amended Entry of appearance for Christina Schwarz as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 11/07/2018 by email. [563412] [17-2173] [Laura Fishwick] [Entered: 11/07/2018 04:53 PM] (4) |
| Nov 7, 2018 | 71 | Amended Entry of appearance for Christopher E. Loh as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 11/07/2018 by email. [563411] [17-2173] [Laura Fishwick] [Entered: 11/07/2018 04:51 PM] (4) |
| Nov 7, 2018 | 70 | Amended Entry of appearance for Nicholas N. Kallas as principal counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 11/07/2018 by email. [563410] [17-2173] [Laura Fishwick] [Entered: 11/07/2018 04:49 PM] (4) |
| Jul 27, 2018 | 69 | **TEXT ONLY** ORDER granting motion to withdraw attorney Charlotte Jacobsen [68] filed by Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [538921] [JAB] [Entered: 07/27/2018 08:51 AM] (0) |
| Jul 26, 2018 | 68 | MOTION of Appellants Novartis AG and Novartis Pharmaceuticals Corporation to withdraw counsel Charlotte Jacobsen [Consent: unopposed]. Service: 07/26/2018 by email. [538766] [17-2173] [Christina Schwarz] [Entered: 07/26/2018 01:46 PM] (7) |
| Jul 3, 2018 | 67 | Certificate of Interest for the Appellee West-Ward Pharmaceuticals International Limited. Service: 07/03/2018 by email. [533601] [17-2173] [Keith Zullow] [Entered: 07/03/2018 05:59 PM] (3) |
| Jun 15, 2018 | 66 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellee West-Ward Pharmaceuticals International Limited. Service: 06/15/2018 by email. [530037] [17-2173] [William Jay] [Entered: 06/15/2018 04:58 PM] (7) |
| Jun 4, 2018 | 65 | Submitted after ORAL ARGUMENT by Christina A. L. Schwarz for Novartis AG and Novartis Pharmaceuticals Corporation and William M. Jay for Par Pharmaceutical, Inc., West-Ward Pharmaceuticals International Limited and Breckenridge Pharmaceutical Inc. Panel: Judge: Prost , Judge: Wallach , Judge: Chen. [526605] [JAB] [Entered: 06/04/2018 01:12 PM] (0) |
| May 15, 2018 | 64 | Response to oral argument order from the Appellees Par Pharmaceutical, Inc., West-Ward Pharmaceuticals International Limited and Breckenridge Pharmaceutical Inc.. Designating William M. Jay to argue.. Designating 15 minutes for argument. [17-2173] [William Jay] [Entered: 05/15/2018 02:45 PM] (0) |
| May 15, 2018 | 63 | Response to oral argument order from the Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Designating Christina Schwarz to argue.. Designating 12 minutes for argument. Reserving 3 minutes for rebuttal. [17-2173] [Christina Schwarz] [Entered: 05/15/2018 02:26 PM] (0) |
| Apr 20, 2018 | 62 | NOTICE OF CALENDARING. Panel: 1806C. Case scheduled Jun 04, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to oral argument order due: 05/15/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [515655] [JAB] [Entered: 04/20/2018 01:39 PM] (0) |
| Apr 17, 2018 | 61 | ORDER filed. The motion [59] is granted to the extent that these appeals will be placed on the June oral argument calendar. Service: 04/17/2018 by clerk. [514146] [LMS] [Entered: 04/17/2018 02:11 PM] (2) |
| Apr 17, 2018 | 60 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: West-Ward's motion [59] selected an incorrect relief ("expedite other"). CORRECTION: When requesting expedited oral argument in a case the correct relief is "expedite hearing." Please ensure future motions select the correct relief. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [513997] [MJL] [Entered: 04/17/2018 09:48 AM] (0) |
| Apr 16, 2018 | 59 | MOTION of Appellee West-Ward Pharmaceuticals International Limited to expedite. [Consent: unopposed]. Service: 04/16/2018 by email. [513902] [17-2173] [William Jay] [Entered: 04/16/2018 07:14 PM] (9) |
| Feb 13, 2018 | 58 | Notice from Appellee West-Ward Pharmaceuticals International Limited regarding conflicts with oral argument (April 5-6, April 9, May 2-3, June 5, June 7 ). Service: 02/13/2018 by email. [497404] [William Jay] [Entered: 02/13/2018 03:01 PM] (2) |
| Dec 1, 2017 | 57 | 6 paper copies of the Joint Appendix [53] received from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. [479582] [CW] [Entered: 12/01/2017 11:55 AM] (0) |
| Nov 29, 2017 | 56 | Notice from Appellants Novartis AG and Novartis Pharmaceuticals Corporation regarding conflicts with oral argument (February 5-9 and 12). Service: 11/29/2017 by email. [478919] [Laura Fishwick] [Entered: 11/29/2017 01:47 PM] (2) |
| Nov 28, 2017 | 55 | Notice from Appellee West-Ward Pharmaceuticals International Limited regarding conflicts with oral argument (February 7-9, March 8, April 5 ). Service: 11/28/2017 by email. [478525] [William Jay] [Entered: 11/28/2017 10:53 AM] (2) |
| Nov 22, 2017 | 54 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 11/29/2017. [477783] [FMS] [Entered: 11/22/2017 11:31 AM] (0) |
| Nov 21, 2017 | 53 | APPENDIX FILED for Novartis AG and Novartis Pharmaceuticals Corporation [52]. Number of Pages: 331. Service: 11/21/2017 by email. The paper copies of the brief should be received by the court on or before 12/01/2017. [477782] [FMS] [Entered: 11/22/2017 11:30 AM] (331) |
| Nov 21, 2017 | 52 | TENDERED from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Title: JOINT APPENDIX. Service: 11/21/2017 by email. [477422] [Laura Fishwick] [Entered: 11/21/2017 01:21 PM] (331) |
| Nov 17, 2017 | 51 | 6 paper copies of the Reply Brief [49] received from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. [476542] [CW] [Entered: 11/17/2017 12:23 PM] (0) |
| Nov 16, 2017 | 50 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Novartis AG, Novartis Pharmaceuticals Corporation and Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited. Service: 11/16/2017 by email. [476081] [Laura Fishwick] [Entered: 11/16/2017 10:19 AM] (5) |
| Nov 14, 2017 | 49 | REPLY BRIEF FILED for Appellants Novartis AG and Novartis Pharmaceuticals Corporation [48]. Number of Pages: 18. Service: 11/14/2017 by email. The paper copies of the brief should be received by the court on or before 11/27/2017. Appendix is due 11/21/2017. [476064] [FMS] [Entered: 11/16/2017 09:35 AM] (29) |
| Nov 14, 2017 | 48 | TENDERED from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Title: REPLY BRIEF. Service: 11/14/2017 by email. [475514] [Laura Fishwick] [Entered: 11/14/2017 05:19 PM] (29) |
| Oct 27, 2017 | 47 | 6 paper copies of the Opening Response Brief [43] received from Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited. [471094] [CW] [Entered: 10/27/2017 12:48 PM] (0) |
| Oct 27, 2017 | 46 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Appellants' motions [30] and [44] did not include a certificate of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions must contain a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [471077] [MJL] [Entered: 10/27/2017 12:07 PM] (0) |
| Oct 27, 2017 | 45 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [44] filed by Appellants Novartis AG and Novartis Pharmaceuticals Corporation. The brief is due 11/14/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [471075] [MJL] [Entered: 10/27/2017 12:05 PM] (0) |
| Oct 26, 2017 | 44 | MOTION of Appellants Novartis AG and Novartis Pharmaceuticals Corporation to extend the time to 11/14/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 10/26/2017 by email. [470925] [Laura Fishwick] [Entered: 10/26/2017 05:58 PM] (9) |
| Oct 24, 2017 | 43 | BRIEF FILED for Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited [42]. Number of Pages: 33. Service: 10/24/2017 by email. The paper copies of the brief should be received by the court on or before 11/02/2017. Appellants Novartis AG and Novartis Pharmaceuticals Corporation reply brief is due 11/07/2017. [470828] [FMS] [Entered: 10/26/2017 02:19 PM] (49) |
| Oct 24, 2017 | 42 | TENDERED from Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited. Title: RESPONSE BRIEF. Service: 10/24/2017 by email. [470258] [William Jay] [Entered: 10/24/2017 08:34 PM] (49) |
| Oct 2, 2017 | 41 | **TEXT ONLY** ORDER granting motion to extend time to file appellee's principal brief [40] filed by Appellees Par Pharmaceutical, Inc., Breckenridge Pharmaceutical Inc. and West-Ward Pharmaceuticals International Limited. Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited brief is due 10/24/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [464599] [FMS] [Entered: 10/02/2017 09:54 AM] (0) |
| Sep 29, 2017 | 40 | MOTION of Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited to extend the time to 10/24/2017 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/29/2017 by email. [464378] [William Jay] [Entered: 09/29/2017 01:50 PM] (9) |
| Sep 18, 2017 | 39 | Entry of appearance for Daniel R. Evans as of counsel for Appellee Breckenridge Pharmaceutical Inc.. Service: 09/18/2017 by email. [461879] [Rachel Hughey] [Entered: 09/18/2017 06:32 PM] (2) |
| Sep 1, 2017 | 38 | 6 paper copies of the Opening Brief [37] received from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. [458230] [CW] [Entered: 09/01/2017 10:42 AM] (0) |
| Aug 29, 2017 | 37 | BRIEF FILED for Appellants Novartis AG and Novartis Pharmaceuticals Corporation [36]. Number of Pages: 48. Service: 08/29/2017 by email. The paper copies of the brief should be received by the court on or before 09/08/2017. Appellees Breckenridge Pharmaceutical Inc., Par Pharmaceutical, Inc. and West-Ward Pharmaceuticals International Limited brief is due 10/10/2017. [457981] [FMS] [Entered: 08/31/2017 10:49 AM] (184) |
| Aug 29, 2017 | 36 | TENDERED from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Title: OPENING BRIEF. Service: 08/29/2017 by email. [457569] [Christina Schwarz] [Entered: 08/29/2017 10:16 PM] (184) |
| Aug 29, 2017 | 35 | TENDERED from Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Title: OPENING BRIEF. Service: 08/29/2017 by email. [457562]. This brief has been corrected. See Doc. No. [37]. [Christina Schwarz] [Entered: 08/29/2017 07:30 PM] (0) |
| Aug 29, 2017 | 34 | Entry of appearance for Laura K. Fishwick as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 08/29/2017 by email. [457392] [Christina Schwarz] [Entered: 08/29/2017 02:05 PM] (3) |
| Aug 29, 2017 | 33 | Entry of appearance for Charlotte Jacobsen as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 08/29/2017 by email. [457388] [Christina Schwarz] [Entered: 08/29/2017 02:02 PM] (3) |
| Aug 2, 2017 | 32 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [450836] [JCA] [Entered: 08/02/2017 09:56 AM] (0) |
| Jul 27, 2017 | 31 | **TEXT ONLY** ORDER granting motion to extend time to file appellant's principal brief [30] filed by Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Brief is due 08/29/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [449671] [FMS] [Entered: 07/27/2017 11:25 AM] (0) |
| Jul 26, 2017 | 30 | MOTION of Appellants Novartis AG and Novartis Pharmaceuticals Corporation to extend the time to 08/29/2017 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 07/26/2017 by email. [449477] [Christina Schwarz] [Entered: 07/26/2017 03:03 PM] (9) |
| Jun 30, 2017 | 29 | Entry of appearance for Brenda L. Danek as of counsel for Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443647] [Brenda Danek] [Entered: 06/30/2017 04:44 PM] (3) |
| Jun 30, 2017 | 28 | Entry of appearance for Robert J. Gajarsa as of counsel for Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443646] [Robert Gajarsa] [Entered: 06/30/2017 04:40 PM] (3) |
| Jun 30, 2017 | 27 | Entry of appearance for Marc N. Zubick as of counsel for Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443644] [Marc Zubick] [Entered: 06/30/2017 04:36 PM] (3) |
| Jun 30, 2017 | 26 | Entry of appearance for Gabriel K. Bell as of counsel for Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443642] [Gabriel Bell] [Entered: 06/30/2017 04:33 PM] (3) |
| Jun 30, 2017 | 25 | Docketing Statement for the Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443641] [Daniel Brown] [Entered: 06/30/2017 04:29 PM] (5) |
| Jun 30, 2017 | 24 | Certificate of Interest for the Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443640] [Daniel Brown] [Entered: 06/30/2017 04:28 PM] (3) |
| Jun 30, 2017 | 23 | Entry of appearance for Daniel G. Brown as principal counsel for Appellee Par Pharmaceutical, Inc.. Service: 06/30/2017 by email. [443639] [Daniel Brown] [Entered: 06/30/2017 04:26 PM] (3) |
| Jun 30, 2017 | 22 | Docketing Statement for the Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 06/30/2017 by email. [443606] [Christina Schwarz] [Entered: 06/30/2017 03:51 PM] (5) |
| Jun 30, 2017 | 21 | Certificate of Interest for the Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 06/30/2017 by email. [443604] [Christina Schwarz] [Entered: 06/30/2017 03:49 PM] (2) |
| Jun 30, 2017 | 20 | Entry of appearance for Christopher E. Loh as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 06/30/2017 by email. [443601] [Christina Schwarz] [Entered: 06/30/2017 03:47 PM] (3) |
| Jun 30, 2017 | 19 | Entry of appearance for Christina Schwarz as of counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 06/30/2017 by email. [443599] [Christina Schwarz] [Entered: 06/30/2017 03:45 PM] (3) |
| Jun 30, 2017 | 18 | Entry of appearance for Nicholas N. Kallas as principal counsel for Appellants Novartis AG and Novartis Pharmaceuticals Corporation. Service: 06/30/2017 by email. [443594] [Christina Schwarz] [Entered: 06/30/2017 03:43 PM] (3) |
| Jun 30, 2017 | 17 | CORRECTED certificate of service for Appellee Breckenridge Pharmaceutical Inc. for attorney entry of appearance , Doc No. [5], attorney entry of appearance , Doc No. [6], attorney entry of appearance , Doc No. [7], certificate of interest , Doc No. [8], docketing statement , Doc No. [9]. Service: 06/30/2017 by email. [443580] [Rachel Hughey] [Entered: 06/30/2017 03:25 PM] (3) |
| Jun 30, 2017 | 16 | Docketing Statement for the Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443478] [Keith Zullow] [Entered: 06/30/2017 01:11 PM] (4) |
| Jun 30, 2017 | 15 | Certificate of Interest for the Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443476] [Keith Zullow] [Entered: 06/30/2017 01:08 PM] (4) |
| Jun 30, 2017 | 14 | Entry of appearance for Naomi Birbach as of counsel for Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443475] [Keith Zullow] [Entered: 06/30/2017 01:07 PM] (4) |
| Jun 30, 2017 | 13 | Entry of appearance for Michael B. Cottler as of counsel for Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443474] [Keith Zullow] [Entered: 06/30/2017 01:05 PM] (4) |
| Jun 30, 2017 | 12 | Entry of appearance for Steven J. Bernstein as of counsel for Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443472] [Keith Zullow] [Entered: 06/30/2017 01:04 PM] (4) |
| Jun 30, 2017 | 11 | Entry of appearance for William M. Jay as of counsel for West-ward Pharmaceuticals International Ltd. Service: 06/30/2017 by email. [443471]--[Edited 06/30/2017 by JP] [Keith Zullow] [Entered: 06/30/2017 01:02 PM] (4) |
| Jun 30, 2017 | 10 | Entry of appearance for Keith A. Zullow as principal counsel for Appellee West-ward Pharmaceuticals International Limited. Service: 06/30/2017 by email. [443469] [Keith Zullow] [Entered: 06/30/2017 01:00 PM] (4) |
| Jun 30, 2017 | 9 | Docketing Statement for the Appellee Breckenridge Pharmaceutical Inc.. Service: 06/30/2017 by email. [443467] [Rachel Hughey] [Entered: 06/30/2017 12:56 PM] (3) |
| Jun 30, 2017 | 8 | Certificate of Interest for the Appellee Breckenridge Pharmaceutical Inc.. Service: 06/30/2017 by email. [443465] [Rachel Hughey] [Entered: 06/30/2017 12:54 PM] (1) |
| Jun 30, 2017 | 7 | Entry of appearance for Christopher J. Sorenson as of counsel for Appellee Breckenridge Pharmaceutical Inc.. Service: 06/30/2017 by email. [443462] [Rachel Hughey] [Entered: 06/30/2017 12:53 PM] (1) |
| Jun 30, 2017 | 6 | Entry of appearance for B. Jefferson Boggs as of counsel for Appellee Breckenridge Pharmaceutical Inc.. Service: 06/30/2017 by email. [443460] [Rachel Hughey] [Entered: 06/30/2017 12:52 PM] (1) |
| Jun 30, 2017 | 5 | Entry of appearance for Rachel C. Hughey as principal counsel for Appellee Breckenridge Pharmaceutical Inc.. Service: 06/30/2017 by email. [443458] [Rachel Hughey] [Entered: 06/30/2017 12:50 PM] (1) |
| Jun 23, 2017 | 4 | Official caption revised. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [441783] [FMS] [Entered: 06/23/2017 03:31 PM] (0) |
| Jun 23, 2017 | 3 | Note to file: The following cases are associated:17-2173 Lead with 2017-2175, 2017-2176, 2017-2178, 2017-2179, 2017-2180, 2017-2182, 2017-2183, 2017-2184 Consolidated. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [441778] [17-2173, 17-2175, 17-2176, 17-2178, 17-2179, 17-2180, 17-2182, 17-2183, 17-2184] [FMS] [Entered: 06/23/2017 03:25 PM] (0) |
| Jun 23, 2017 | 2 | ORDER consolidating appeals (17-2173 Lead with 2017-2175, 2017-2176, 2017-2178, 2017-2179, 2017-2180, 2017-2182, 2017-2183, 2017-2184 Consolidated ). Service as of this date by Clerk of Court. [441775] [17-2173, 17-2175, 17-2176, 17-2178, 17-2179, 17-2180, 17-2182, 17-2183, 17-2184] [FMS] [Entered: 06/23/2017 03:19 PM] (2) |
| Jun 16, 2017 | 1 | Appeal docketed. Received: 06/15/2017. [439963]Entry of Appearance due 06/30/2017. Certificate of Interest is due on 06/30/2017. Docketing Statement due 06/30/2017. Appellant/Petitioner's brief is due 08/15/2017. [FMS] [Entered: 06/16/2017 12:02 PM] (62) |
